Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
IDEAYA Biosciences ( (IDYA) ) has shared an announcement.
On December 9, 2025, GlaxoSmithKline notified IDEAYA Biosciences of its decision to terminate their collaboration and license agreement, effective March 9, 2026. During the transition period, GSK will transfer two clinical programs back to IDEAYA, which will assess its strategic options for these programs in 2026, without affecting its cash runway expectations into 2030.
The most recent analyst rating on (IDYA) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.
Spark’s Take on IDYA Stock
According to Spark, TipRanks’ AI Analyst, IDYA is a Neutral.
IDEAYA Biosciences’ overall stock score reflects significant financial challenges and a negative valuation due to ongoing losses. However, technical analysis shows strong momentum, and recent positive clinical trial results provide a potential upside. The termination of a major collaboration poses strategic risks, but the company’s strong equity position offers some stability.
To see Spark’s full report on IDYA stock, click here.
More about IDEAYA Biosciences
IDEAYA Biosciences operates in the biotechnology industry, focusing on the development of precision medicine and immuno-oncology therapies.
Average Trading Volume: 1,122,462
Technical Sentiment Signal: Buy
Current Market Cap: $2.95B
See more insights into IDYA stock on TipRanks’ Stock Analysis page.